Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
-
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
-
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
-
Subaru Selects Dynamic Map Platform’s HD Map Data for New Advanced EyeSight® Driver Assist Technology
-
Everseen Unveils Everact: The First Agentic AI Platform for Conversational Retail Intelligence
-
Mobileye Announces Timing of its Fourth Quarter and Full Year 2025 Results
-
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
-
K Wave Media Leads Investment in “Once We Were Us,” Now the #1 Film at the Korean Box Office
-
Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana Validator
-
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
-
Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
-
Surge Copper Appoints Jennifer Anthony as Vice President, Environment and Regulatory Affairs
-
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
-
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
-
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
-
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
-
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
-
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
-
NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026
-
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
-
KEY Investment Partners Acquires BellRock Brands’ Portfolio, Home of Mary’s Medicinals, Dixie and Other Top Names
-
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
-
Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 3, 2026
-
Amplify ETFs Nominated for ETF Provider of the Year
-
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
-
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
-
Following Completion of Expansion Concept Studies HyProMag USA Advances Expansion to Three States Supporting a Path To Triple U.S. Rare Earth Magnet Capacity by 2029
-
Oatly to Report Fourth Quarter 2025 Financial Results on February 11, 2026
-
NioCorp Reports Final Assay Results From the Department of War-Funded Elk Creek Drilling Campaign
-
GXO Schedules Fourth Quarter, Full-Year 2025 Earnings Conference Call for Wednesday, February 11, 2026
-
Eagle Plains Announces Fully Funded Drill Program at the George Lake Critical Metals Project, Saskatchewan
-
Village Farms International Advances New Product Innovation in the Dutch Market
-
Azarga Metals Announces Non-Brokered Private Placement
-
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
-
Publication of Prospectus
-
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
-
Healthpeak Properties Announces $925 Million of Transaction Activity
-
Reed Duchscher Appointed to Funko Board of Directors
-
Dimensional Fund Advisors Ltd. : Form 8.3 - UNITE GROUP PLC/THE - Ordinary Shares
-
YieldMax® ETFs Announces Distributions on MSST, NVIT, and TEST
-
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
-
Form 8.3 - [IDOX PLC - 09 01 2026] - (CGWL)
-
Genesco Reports Comparable Sales
-
Study Shows NuScale Power Technology Can Support Profitable, Reliable Power for Chemical Plants
-
Pharvaris Outlines 2026 Strategic Priorities
-
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
-
Birkenstock Announces Preliminary Fiscal First Quarter (Ended December 31, 2025) Revenue Of €402 Million, Growth Of 17.8% In Constant Currency; Report Date And Conference Call
-
Anchor Browser Powers Groq's Agent Platform, Enabling Reliable AI Access to the Web
-
DPM Metals Achieves Gold Production Guidance for the Eleventh Consecutive Year; Announces Timing of Fourth Quarter and Full-Year 2025 Financial Results
-
Spire Global Successfully Launches 9 Satellites on SpaceX’s Twilight Mission
